MetaCap

Odyssey Therapeutics Inc. (ODTX)

NASDAQ: ODTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

16.96-1.38 (-7.52%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ODTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$815.23M
EPS (TTM)
-$6.33
52-week range
15.10 – 29.05
Day range
16.46 – 18.08
Volume / Avg
677.84K / 329.31K
Beta
—

52-week range

$15.10$29.05

ODTX stock today

Odyssey Therapeutics (ODTX) closed at $16.96 on Nov 20, down 7.52% (-$1.38), versus the S&P 500's 3.70% decline. Volume was 2.1x the average at 677.84K shares, a sign of unusually heavy trading. Shares are 41.6% below their 52-week high of $29.05, set on Sep 4, 2026 and 12.3% above the 52-week low of $15.10, near the bottom of the past year's range.

Odyssey Therapeutics has posted a net loss over the last twelve months (EPS of -$6.33), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Odyssey Therapeutics

Company profile

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Gary D. Glick Ph.D.
Headquarters
Boston, MA
Employees
100
IPO year
2026

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$34.67+104.42%

  • Strong buy 2
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $27.00High $42.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-1.10 vs $-1.13
Surprise
+2.65%

ODTX news

All ODTX news

Odyssey Therapeutics peers

Health Care sector
ODTX peer companies
CompanyPrice% ChgMarket capCompare
BBTXBambusa Therapeutics Inc.16.00+2.89%$815.08Mvs ODTX
PRMEPrime Medicine Inc.3.55-7.55%$791.62Mvs ODTX
MGTXMeiraGTx Holdings plc7.98-1.97%$779.89Mvs ODTX
IMTXImmatics N.V.5.77-3.03%$878.58Mvs ODTX
GLUEMonte Rosa Therapeutics Inc.8.64-3.03%$738.29Mvs ODTX
AURAAura Biosciences Inc.6.87-1.58%$714.99Mvs ODTX
SLDBSolid Biosciences Inc.6.25-2.95%$697.57Mvs ODTX
ATTOAttovia Therapeutics Inc.15.10-3.08%$690.26Mvs ODTX

Indexes, lists and sector

Odyssey Therapeutics stock FAQ

What is Odyssey Therapeutics's stock price today?

ODTX last traded at $16.96 as of Nov 20, 4:00 PM EST, down 7.52% on the day. Prices are delayed at least 15 minutes.

Who is Odyssey Therapeutics's CEO?

Dr. Gary D. Glick Ph.D. is the chief executive officer of Odyssey Therapeutics Inc., which has about 100 employees.

What is the ODTX 52-week high?

The 52-week high for ODTX is $29.05 and the 52-week low is $15.10. The stock is currently 41.6% below its high.

Compare ODTX